{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.002","statisticalComment":"Stratified log rank test was conducted, stratifying on the randomization factors","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.603","upperLimit":"0.764","value":"0.683"},{"groupId":"OG001","lowerLimit":"0.453","upperLimit":"0.629","value":"0.541"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the time from randomization to death from any cause. Patients who have not died would be censored at the date of last known alive. 2-year OS rate was defined as a proportion of patients who are alive after two years of follow-up time among all cases who have died within 2 years or alive after 2-year follow-up time. Kaplan-Meier method was used to estimate 2-year OS.","dispersionType":"95% Confidence Interval","groups":[{"description":"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.\n\nIMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression (or before), patients re-register and cross over to Arm C.\n\nPatients also undergo CT, ECHO or MUGA, and collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nComputed Tomography: Undergo CT\n\nEchocardiography Test: Undergo ECHO\n\nIpilimumab: Given IV\n\nMultigated Acquisition Scan: Undergo MUGA scan\n\nNivolumab: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm A (Immunotherapy)"},{"description":"Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression (or before), patients re-register and cross over to Arm D.\n\nPatients also undergo CT, ECHO or MUGA, and collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nComputed Tomography: Undergo CT\n\nDabrafenib Mesylate: Given PO\n\nEchocardiography Test: Undergo ECHO\n\nMultigated Acquisition Scan: Undergo MUGA scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nTrametinib Dimethyl Sulfoxide: Given PO","id":"OG001","title":"Arm B (BRAF Inhibitor Therapy)"}],"paramType":"NUMBER","populationDescription":"All randomized patients (ie, intent-to-treat population)","reportingStatus":"POSTED","timeFrame":"assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry","title":"2-year Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Proportion of participants"}